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Decision support systemsa b s t r a c t
Decision support systems are used as a method of promoting consistent guideline-based diagnosis sup-
porting clinical reasoning at point of care. However, despite the availability of numerous commercial
products, the wider acceptance of these systems has been hampered by concerns about diagnostic per-
formance and a perceived lack of transparency in the process of generating clinical recommendations.
This resonates with the Learning Health System paradigm that promotes data-driven medicine relying
on routine data capture and transformation, which also stresses the need for trust in an evidence-
based system. Data provenance is a way of automatically capturing the trace of a research task and its
resulting data, thereby facilitating trust and the principles of reproducible research. While computational
domains have started to embrace this technology through provenance-enabled execution middlewares,
traditionally non-computational disciplines, such as medical research, that do not rely on a single soft-
ware platform, are still struggling with its adoption. In order to address these issues, we introduce prove-
nance templates – abstract provenance fragments representing meaningful domain actions. Templates
can be used to generate a model-driven service interface for domain software tools to routinely capture
the provenance of their data and tasks. This paper specifies the requirements for a Decision Support tool
based on the Learning Health System, introduces the theoretical model for provenance templates and
demonstrates the resulting architecture. Our methods were tested and validated on the provenance
infrastructure for a Diagnostic Decision Support System that was developed as part of the EU FP7
TRANSFoRm project.
 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The importance of data, its origins and quality, has long been
recognised in clinical research. In recent years, we have also
witnessed increased reliance of clinical practice on data, through
routine data capture in Electronic Health Record systems, quality
improvement initiatives at multiple levels, and growing adoption
of evidence-based medicine.
The patient safety implications of diagnostic error in family prac-
tice are potentially severe for both patient and clinician [1]. The
development of diagnostic clinical decision support systems (DSS)
has long been advocated to promote consistent guideline-based
diagnosis supporting clinical reasoning at point of care. However,
the wider acceptance of these systems in clinical practice has beenmuch slower in happening despite the availability of many com-
mercial products. Concerns remain about diagnostic performance
and a perceived lack of transparency in first generation systems that
deploy an evidence knowledge base in the form of a black box that
generates clinical recommendations. These concerns about the
quality of evidence and the effort required in the longer termmain-
tenance and sustainability of the underlying evidence base support-
ing such systems has lead to research into second generation tools
supporting a more dynamic and iterative cycle of evidence creation
and update using a technical infrastructure developed under the
auspice of the Learning Health System (LHS) [2].
The Learning Health System community envisages every partic-
ipant in the health system (clinician, patient, researcher, insurer. . .)
as both a producer and consumer of data. Central to this vision is
the notion of routine capture, transformation and dissemination
of both data and resulting knowledge. Clinical studies, quality
improvement initiatives, decision support, and other scenarios
can all then be associated with the routes that the data is taking
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needs to be made available at each step of these use cases, to sup-
port auditability and transparency.
When applied to DSS-s, this trust requirement translates to the
ability to readily demonstrate the clinical reasoning that was per-
formed in a clinical encounter, together with the recommendation
received. In addition to supporting the auditability of the process,
this capability also promotes transparency and traceability from
the recommendation back to the rules applied to produce the rec-
ommendation. The data provenance community has been working
on methods for ensuring reproducibility in scientific research,
through use of Semantic Web techniques and the W3C PROV stan-
dard [3], that are highly relevant to the challenges of decision sup-
port in the LHS environment. Computational provenance provides
a uniform data-centred audit trail of what actually happened dur-
ing some task, and we shall describe how these methods can be
adapted to the needs of LHS.
There are two main technical challenges to be addressed in
applying data provenance to the Decision Support System scenar-
io; firstly, how to have heterogeneous, distributed software agents
(security systems, rule engines. . .) construct unified, verifiable
provenance traces, and secondly, how to formally guarantee that
the resulting provenance traces will satisfy domain constraints,
often expressed in ontologies, and user data requirements.
In order to address these issues, we introduce provenance tem-
plates, abstract provenance fragments representing meaningful
domain actions that can be used to generate a model-driven ser-
vice interface for domain software tools to routinely capture the
provenance of their data and tasks. A template defines a prove-
nance graph in a generic manner by means of variables such that
it may be later instantiated and grafted onto pre-existing prove-
nance graphs. Importantly, this paper introduces the idea that tem-
plates may describe subgraphs subject to bounded iteration in both
serial and parallel manner.
The EU FP7 TRANSFoRm project [4] has developed a diagnostic
decision support tool that promotes numerous state-of-the-art
practices of good clinical decision support. These include precisely
defined usability patterns, integration with an electronic health
record (EHR), allowing for recommendations at the point of care
as part of the clinician workflow, and a provenance backend that
captures provenance data about the computational aspects of the
diagnostic task.
The paper first introduces the concepts of the Learning Health
System, data provenance and decision support systems in Section 2,
before presenting the requirements of the LHS-enabled DSS, novel
provenance templates formalism and the associated provenance
architecture in Section 3. Section 4 demonstrates how the new
model was used to construct DSS audit trails in TRANSFoRm and
in Section 5 we consider how our approach addresses the wider
LHS requirements for trust in decision support systems, its impact
with respect to some recent developments, and list related work.
Section 6 offers conclusions and presents pointers for future
research.2. Background
We shall now review the Learning Health System paradigm and
the data provenance technologies, and relate them to the chal-
lenges of clinical Decision Support Systems, presenting as an exam-
ple the DSS developed as part of the TRANSFoRm project.2.1. Learning Health System
The Learning Health System (LHS) movement aims to establish
a next-generation healthcare system, ‘‘. . . one in which progress inscience, informatics, and care culture align to generate new knowl-
edge as an ongoing, natural by-product of the care experience, and
seamlessly refine and deliver best practices for continuous
improvement in health and health care.” [5] Each participant in
the LHS, be they clinician, patient, or researcher, acts as a consumer
and a producer of knowledge, with the LHS providing: (a) routine
and secure aggregation of data from multiple sources, (b) conver-
sion of data to knowledge and (c) dissemination of that knowledge,
in actionable form, to everyone who can benefit from it [2]. Thus,
the LHS creates routes for knowledge transfer between different
parts of the health system, thereby increasing its research and
learning capacity.
Different data-driven scenarios, such as decision support sys-
tems, clinical trial recruitment and management, epidemiological
studies, all represent applications within the LHS, each associated
with the movements and processing of data and knowledge. A
number of LHS implementations have been developed at varying
scales [4,6–8].
Attempts to define the core requirements of the Learning Health
System [5] have highlighted concerns about a perceived lack of
transparency and tracking in current systems demonstrating how
clinical reasoning was actually applied in any given clinical case.
A fundamental feature of the LHS is the generation and curation
of clinical evidence using electronic data sources. Such a process
is critically dependent on a full transparency of how evidence is
produced, maintained and consumed as a means of generating
trust in the underlying system. Trust in the evidence base leads
to the acceptance of responsibility for the clinical recommenda-
tions made by it which is essential if these tools are to gain wide-
spread acceptance in the clinical community.
2.2. Data provenance
Put simply, data provenance describes what actually happened
for some data entity to achieve its current form. W3C standards
body defines provenance as a form of contextual resource meta-
data that describes entities and processes involved in producing and
delivering or otherwise influencing that resource. Provenance provides
a critical foundation for assessing authenticity, enabling trust, and
allowing reproducibility. The Office of the National Coordinator
(ONC) for Health IT describes it as attributes about the origin of
health information at the time it is first created and tracks the uses
and permutations of the health information over its lifecycle. Term
data provenance is used to establish the focus on data entities pro-
duced in the processes.
Data provenance provides traceability by automatically captur-
ing the trace of the research task and resulting data in a uniform
and domain-independent way, thereby facilitating reproducible
research. The original concept comes from the eScience and
cyber-infrastructure communities, where it was used for capturing
the exact parameterisations and configurations of scientific work-
flows that produced a particular data set [9,10]. Although the orig-
inal users of provenance data were the scientific programmers
creating and maintaining research workflows, the increasing num-
ber of tools and technologies available resulted in a wide array of
stakeholders who can benefit from provenance information using
visual front-end tools and interactive reports.
2.2.1. PROV model
The provenance technology, as defined in the W3C PROV stan-
dard [3], provides a common platform for automated capture of
metadata about the data artifacts (e.g. databases, individual patient
records, diagnostic recommendations), all processes that use or
create those artifacts, and all actors that participate in those pro-
cesses, such as clinicians, patients, researchers, or computer soft-
ware. The resulting provenance data stores are typically
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software tools in some software system that can be mined for gen-
erating new knowledge, or investigated for audit purposes [11].
PROV is an interoperability standard, so there is no need for
every system to use it as its core data model, or even to use a graph
data model, but the W3C recommendation is for each provenance-
enabled system to support import and export in the PROV format.
Nodes in a provenance graph come in three flavours: entities,
which represent immutable states of a some data for which one
wants to provide a history, activities that produce and consume
such entities and agents associated in some capacity with either
of the former. The edges of a graph represent various inter-
relations between the node types, such as usage, generation, and
association [3]. Validity of graphs is defined using a number of typ-
ing, ordering and impossibility constraints to be checked upon a
normalised form of a graph, if one exists [12]. All nodes have a
mandatory identifier given as a qualified name. A qualified name
consists of an optional namespace followed by a local name of
form ns:name. Identifiers belong to the prov namespace. Nodes
and edges may be annotated with an optional dictionary of
attribute-value pairs, formed of a qualified name and a data value,
which can be used to attach ontological annotations onto nodes,
specifying their meaning in some domain. Fig. 1 demonstrates
these features in diagrammatic form using the standard PROV rep-
resentation of entities as yellow ellipses, activities as blue rectan-
gles and agents as orange pentagons. Node annotations are
shown as dashed grey boxes.2.3. Clinical decision support systems
Decision support systems (DSS) have a long and sometimes
controversial research history [13,14]. Clinical decision support
system is defined as software that is designed to be a direct aid
to clinical decision-making, in which the characteristics of an indi-
vidual patient are matched to a computerised clinical knowledge
base and patient-specific assessments or recommendations are
then presented to the clinician or the patient for a decision [15].Fig. 1. An example PROV graph using the standard representation of entities as
yellow ellipses, activities as blue rectangles and agents as orange pentagons. Node
annotations are shown as dashed grey boxes. (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this article.)The exact nature of the patient-specific assessments or recom-
mendations and the delivery mechanism used to present that
information to the patient or clinician can vary greatly [16]. This
has resulted in a number of different types of clinical decision sup-
port system that address particular clinical areas, ranging from
computerised physician order entry and appropriate medicines
management, via risk calculators, diagnostic aids, and triggered
alerts and reminders to full electronic implementations of clinical
guidelines.
The demonstrable efficacy of DSS in clinical practice however
has been limited. One reason is that research impacts of imple-
menting such systems have frequently been assessed as a technical
driver of process change. Ideally they should more usefully demon-
strate a measurable positive impact on practitioner performance
that leads to directly attributable and measurable improvement
in patient outcomes [17]. But more promising results have been
demonstrated in research environments outside the clinical area
of diagnostics [18–21].
Traditional approaches to diagnostic decision support have
lacked broad acceptance for a number of other well documented
reasons: poor integration with EHRs and clinician workflow, static
black-box rule based evidence that lacks transparency and trust,
usage of proprietary technical standards hindering wider interop-
erability [22,18,23–25]. Despite these problems there is an increas-
ing recognition of the need to realise the potential value of
implementing decision support systems more generally. This is
reflected in their inclusion as important components of wider gov-
ernment ICT based health policy legislation in practice [26,27].
The evolution of clinical decision support development reflects
attempts to address workflow and integration issues, interoper-
ability standards and also separation of the knowledgebase as a
separate service distinct from the tools themselves [28]. The focus
has largely been on implementations of what can be described as
diagnostic symptom checkers, relying on a knowledge base defined
as a series of rules in the form of a database of knowledge facts.
These may be triggered or combined together in the form of guide-
lines based on statements using a knowledge rule languages or rule
engines such as Arden Syntax [29], GLIF [30] and GELLO [31]. These
approaches have led to a recent shift towards model-based
approaches to knowledge representation for the purposes of clini-
cal decision support [32].
2.4. TRANSFoRm decision support system
The EU FP7 TRANSFoRm project (2010–2015) [4], working with
20 partners in 10 European countries, developed and evaluated a
single unified international platform to support main Learning
Health System scenarios that combine research and clinical prac-
tice, and reduce barriers to entry for using Electronic Health Record
(EHR) systems and large medical data sources. The project devel-
oped a next generation diagnostic decision support tool that
addresses many of the issues highlighted as being essential for
good clinical decision support [22]. These include integration with
an electronic health record (EHR) allowing for recommendations at
the point of care as part of the clinician workflow. An essential part
that is the subject of this research paper has been the support for
the LHS concepts of transparent generation and use of evidence
in this system.
A prototype next generation diagnostic decision support system
was developed in TRANSFoRm as part of a wider Learning Health
System infrastructure. The tool, shown in Fig. 2 is driven by clinical
knowledge obtained through a web service based clinical evidence
repository providing model driven prompting and recording of
coded patient diagnostic cues supporting diagnosis of 78 clinical
conditions. The diagnostic decision support tool is embedded and
interoperable with the workflow of an EHR system in family
Fig. 2. TRANSFoRm diagnostic decision support tool.
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bottom-up input of observed patient cues (left-hand window) or
top-down drilling into and selection of evidence cues supporting a
specific diagnosis for investigation (right-hand window). A dynami-
cally updated cue count is maintained for each differential diagnosis
indicating the number of evidence cues observed as present for each
diagnosis based on the patient cues recorded during the consulta-
tion. This allows dynamic ranking of potential differential diagnoses
being considered (the most likely at the top) based on the patient
presenting reason for encounter, along with a record of the evidence
supporting each diagnosis under consideration. Upon exiting the tool
a working diagnosis can be confirmed and the coded evidence cues
and current working diagnosis can be saved back and recorded for
future reference in the patient EHR. A diagnostic evidence ontology
[33] was created to serve as the central information model for the
DSS tasks, supporting provision of diagnostic evidence for over 70
diagnostic conditions to decision support consumers using a web
service interface. The evidence content can either be manually
curated or populated using a separately developed data mining
module [34]. The DSS system used the provenance infrastructure
that forms a core part of the TRANSFoRm middleware, together
with the security framework and semantic interoperability
modules.3. Material and methods
We shall now look into how TRANSFoRm implemented the
provenance infrastructure for its diagnostic decision support
system. First, we shall present the requirements stemming from
the context of the Learning Health System, and then present the
theoretical framework for provenance template architecture.1 http://www.inps.co.uk/vision.3.1. Reproducibility requirements of a provenance-enabled decision
support system
To inform our design for provenance templates as means of
implementing reproducibility in DSS, we now establish the repro-
ducibility requirements for a provenance-enabled DSS, by placing
them in the context of the key Learning Health System challenges
[5]:
 An LHS that is trusted and valued by the public and all stakehold-
ers. Privacy, security, and transparency are key elements related
to building public trust and generating value. Trust and confi-
dence at all stages of the LHS operation are essential; from
inputs to outputs (and outcomes). This implies the need for
traceability - a continuous trail of data artifacts and operations
on those artifacts, starting from the data creation (e.g. routine
data capture or import from a data source) through the trans-
formations (knowledge base processing, rule application) all
the way to recommendations made by the DSS.
 An adaptable, self-improving, stable, certifiable, and responsive
LHS. In the context of an adaptable system, how do we deter-
mine what adapts? How can a system adaptably ingest, man-
age, refine, and emit data from a rapidly growing source
environment? What evidence must be gathered about the
development, design, and operation of the system and about
the environment in which it operates to enable certification?
The LHS software architectures need to provide a mechanism
for such evidence to be routinely curated - gathered, organized,
interpreted, and maintained.
 An LHS capable of engendering a virtuous cycle of health improve-
ment. How do we develop ways to communicate the generated
results, information, or knowledge to others who may wish to
replicate (or build upon) the work done, as well as to the gen-
eral public? How can the computational procedures employed
2 Indeed, the original TRANSFoRm implementation was based on Open Provenance
Model [37], a precursor to PROV.
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tent, understandable, checkable, and repeatable, and how can
the computational provenance of derived data be tracked from
its points of production through consumption and use? These
features rely on permanent auditability of the system, with
all necessary audit data being automatically generated from
the provenance traces, and the models.
Based on these, we define the key reproducibility requirements
that apply to decision support.
1. System transparency. The black box approach and lack of
transparency results in the lack of trust and is cited as one of
the main reasons behind the poor take-up of clinical decision
support systems [35]. Therefore, in a provenance-enabled DSS,
activities related to usage and generation of evidence need to
be readily available for users to review.
2. Auditability of recommendations. Medical/legal liability con-
cerns are considered a potential stumbling block for Decision
Support Systems [22], in that it is unclear who takes responsi-
bility for various elements in the DSS that could potentially go
wrong. This relates to the auditability of the system, which
must enable the user to look up a diagnostic recommendation
and find all the relevant detail about how it was made - evi-
dence base used, patient cues entered, software employed.
The level of detail captured must be validated against the
required report granularity.
3. Understandability of data. The data that is captured about the
workings of the DSS needs to be not only accessible to the users
(clinicians, auditors, researchers, patients) but it has to rely on
standardised concepts expressed in terminologies the users
are familiar with.
4. Validation readiness. In order to guarantee that the prove-
nance metadata being captured is at the right level of granular-
ity and encompasses all the necessary features, the structure of
the provenance data needs to be modelled and verified sepa-
rately from the software implementation.
5. Traceability of evidence. The evidence repository will evolve
through the lifecycle of any recommendation software. It is
imperative that the content of the repository is subject to an
orderly release cycle and an associated quality assurance proce-
dure, including an evidence curation process. This is to ensure
that the exact versions of the knowledge bases used in each
specific recommendation can be traced back and analysed if
needed.
6. Reproducibility of recommendations. An underlying feature
for a number of these characteristics is that the recommenda-
tions made by the system are consistent and reproducible. An
identical set of patient cues presented to the same knowledge
base and evidence service software have to always yield the
same result if there is to be trust in the system. This is the core
principle of reproducibility which needs to be demonstrable and
verifiable.
7. Responsibility. While the ultimate responsibility for a diagno-
sis rests with the user who receives the recommendation and
decides what to do with it, in the LHS enabled DSS, the respon-
sibility is shared with the authors of the knowledge base, evi-
dence curators, authors of the reasoning algorithms used, and
others. Thus, tracing both the actors using the evidence and
the ones generating the evidence is required in order for full
accountability to be achieved.
8. Privacy and security. Traditionally, security logs have been
used to keep track of what is going on in the system and inves-
tigate any inappropriate actions. The provenance model needs
to go beyond that and be able to demonstrate that the patient
data is never used contrary to some set of rules. Furthermore,the transformations and anonymisations on patient data need
to be captured in order for the trace to be validated against pri-
vacy constraints.
9. Usability and scalability. An important feature of provenance
support in the DSS is not to do harm, and does not impede the
normal running of the DSS. This requires seamless integration
with no noticeable degradation in performance that would
adversely affect the clinician in their daily routines. Further-
more, the system must be able to scale up in line with the
expected usage volume, so the provenance store needs to be
appropriately specified to cope with accumulation of usage data
over time.
These nine requirements were used to guide the design of our
provenance solution. We shall now introduce the theory behind
provenance templates.3.2. Provenance templates
Data provenance originated in research communities that rely
on uniform computational infrastructures, such as life and earth
sciences. The resulting techniques [36] are not directly applicable
to LHS scenarios and decision support systems, due to heterogene-
ity of software systems involved and the need to ensure consis-
tency of provenance graphs produced by different systems. To
that end, we introduce provenance templates as abstractions that
have domain meaning and can easily be mapped to the actions
of the client software tools. The formalism described here is based
on W3C PROV [3] as the current standard for representing prove-
nance data as graph models. However, the authors can see no bar-
riers to generalising the approach to any graph-based provenance
representation.2
Informally, a provenance template is an abstract provenance
graph which may be instantiated to generate a concrete prove-
nance graph, possibly connected to some existing graph structure.
We refer to that instantiation process together with associated
linkage and validation steps as graph generation. The template
may contain fragments which are to be repeated, for example, a
series of editing operations on some data, and it may specify the
places where the generated graph will be grafted (attached) onto
some existing graph.
A template, T, is a provenance graph with some reserved anno-
tations, as described in Section 2.2.1, using a new provenance
graph template namespace, pgt. A variable is a placeholder for
the node identifier to be provided during generation process, that
uses namespace var, e.g. var:x, var:y, var:z, etc. Nodes in tem-
plates may have variable identifiers or normal fixed identifiers. The
former are referred to as variable nodes and the latter fixed
nodes. Value variables are placeholders for values of attribute-
value annotation, rather than node identifiers and use the names-
pace vvar, e.g.vvar:a, vvar:b, vvar:c. Variables are used to iden-
tify abstract nodes in the template, and value variables to represent
abstract properties associated with either nodes or edges. The
scope of variables and value variables is the entire template and
each distinct variable or value variable must occur only once in a
template. tvarsðTÞ denotes the set of all variables and value vari-
ables occurring in a template T.
Fig. 3 shows a simple template T1, in diagrammatic form. There,
ent1 and act1 are fixed nodes representing respectively a con-
crete entity and activity, whereas var:x, y and var:z are respec-
tively an entity, an activity and an agent whose identifiers have
been replaced by variables. vvar:a is a value variable taking the
Fig. 3. Template T1.
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var:x.
The node act1 is annotated with the type value Concept taken
from ontology myOntology. In this way the semantic type of the
node is constrained, allowing us to assign clear domain meaning
to the concepts in the templates.3.2.1. Series and parallel zones
An important requirement for our templates is to represent rep-
etition in provenance graphs, often used to describe similar seg-
ments that are created by repeated instantiations of a template.
The concept of a repeated pattern in a template is represented
using a zone Z, a connected subgraph that is to be iterated either
in series or in parallel upon generation of the graph. The attributes
of zones belong to the new zone namespace. Each zone has a
unique identifier, zone:id and may optionally be assigned mini-
mum and maximum bounds zone:min and zone:max, setting
the minimum and maximum number of iterations allowed for
the zone. minðZÞ and maxðZÞ respectively denote the minimum
and maximum bounds of the zone Z, if such values are defined.
A zone is defined by the set of template nodes which belong to
it. A node may only belong to one zone. A node that belongs to a
zone is denoted an internal node Ni, and its identifier must be a
variable. Each internal node of a zone is also annotated with the
zone identifier using the pgt:zone attribute, and inherits the
zone’s type and bounds. In the figures below, for readability pur-
poses, zones are represented as frames around associated internal
nodes, in practice they are still PROV annotations, as described in
Section 2.2.1. A value variable is deemed to belong to a zone if it
occurs in an annotation of an internal node of that zone. Let
zvarsðZÞ denote the set of variables and value variables belonging
to a given zone Z.
An external node, N, is any node of a template that does not
belong to a zone. A fixed external node represents a constant node
with a fixed value that is not instantiated further. Any external node
of a template may also act as a graft node, annotated with the
pgt:graft flag, serving as the point at which the template instance
can be linked to another graph. A fixed graft node may share the
identifier of a node from a pre-existing graph and similarly a vari-
able graft node may be given an existing node identifier upon sub-
stitution. We write tvarsðTÞ to represent the set of variables and
value variables belonging to external nodes of a template T.Every edge of a graph has a unique identifier. If the edge is
between two internal nodes, it is called an internal edge, while
an edge between two external nodes of a template T is called an
external edge. Edges that enter and exit the zone are called entry
and exit edges, respectively. The entry and exit edges of a zone
define the manner in which the subgraphs generated by zone iter-
ations are connected to the instantiated external nodes of the
template.
A zone may be iterated in parallel or in series, specified by the
zone:type attribute that can take values of parallel or series
respectively. Intuitively, a parallel iteration represents provenance
derivations which may happen independently, where the entry
and exit edges of the zone are duplicated to create forking and syn-
chronising points respectively in the final graph, whereas a series
type zone represents one which is repeated in sequential fashion
and the entry and exit edges define the connection to an initial
and terminal state.
A parallel zone must have at least one entry or exit edge in
order to ensure graph connectedness upon generation. Series type
zones have some additional notation and requirements. A recur-
sive edge is a virtual edge of a template by which generated serial
iterations of a zone are to be joined. Each such edge defines a con-
nection to be generated from the instantiation of an internal node
in one iteration to the instantiation of an internal node in the fol-
lowing iteration. Such an edge is declared by annotating the exit
node of the edge with the identifier of the entry node as the value
of the pgt:rec_entry attribute. The entry node must be another
internal node belonging to the same zone. Write recðZÞ for the set
of recursive edges of a zone Z. Each node given a value for the
pgt:rec_entry attribute must also be given a value for the pgt:
rec_type specifying the PROV type of the edge to be created. Each
series type zone must have at least one recursive edge to ensure a
graph generated from the template is connected.
A template is valid if it is a valid provenance graph as defined by
[12] and also such that all recursive edges defined in the template
also conform to the typing and impossibility constraints applied to
normal graph edges.
Fig. 4 shows a larger template T2, based upon T1 in which the
previous graph has now been identified as a parallel zone, zone1.
The nodes ent1 and act1 are now identified by the variables var:
u and var:t because all internal nodes of a zone must have vari-
ables as identifiers. The graph has been extended with new exter-
nal nodes, some fixed, ent2, act2, ent3, and some variable var:w
Fig. 4. Template T2 with a parallel zone.
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zone has been annotated with the zone:min attribute so as to
require a minimum of two iterations upon generation.
Fig. 5 shows another template T3 in which the original graph
has again been identified as a zone but this time of series type.
The variable node var:u has been annotated with the values for
the pgt:rec_entry and pgt:rec_type attributes, to specify the
creation of used edges from each instance of var:u to the instance
of var:x in the following iteration of the zone. The number of iter-
ations of the zone has been limited to eight by use of the zone:max
attribute. The graph has been expanded with further external
nodes in the same way as for Fig. 4.
The resulting provenance graphs generated from these tem-
plates are shown at the end of the next section.
3.3. Template generation
The generation of a particular instantiation of a provenance
graph, G, from a template is specified by a substitution. A substi-
tution S is defined as a mapping from a pair comprising a qualified
name and a non-negative integer representing the iteration num-
ber to a PROV value. Thus note that no variables or value variables
remain after a substitution has been performed. The iteration
number for the values substituted for external variables and valuevariables of a template and for those occurring in the first iteration
of any zone is zero. Values substituted for variables or value vari-
ables in any subsequent iterations of a zone are numbered sequen-
tially in the obvious manner.
To encode the templates in a standard way, we extend the nota-
tion of PROV-N [38] by introducing a new predicate name sub and
writing a substitution as a list of expressions of the form
subðqn; i; valÞ, where qn is the qualified name of a variable or
value variable, i is a non-negative integer and val the value to be
substituted for that name in that particular iteration.
In order for a substitution to be valid, every variable or value
variable has to have at least one value to be substituted and if mul-
tiple instantiations of a zone are given, all variables and value vari-
ables belonging to that zone must be given a value to be
substituted in each iteration, and these iterations must be num-
bered in increasing order. The total number of iterations to be
made for a zone Z specified in a substitution S is written
boundðZ; SÞ and must fall within any given minimum or maximum
bound constraints given for the zone, that is,
minðZÞ 6 boundðZ; SÞ 6 maxðZÞ. Finally, for each variable,
p 2 tvarsðTÞ, every value given for p in S must be a PROV identifier,
which must not occur in any pre-existing graph except if the node
to which v belongs has been labelled as a graft node. (Value vari-
ables may be substituted for any PROV value.)
Fig. 5. Template T3 with a series zone.
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single-step when given a complete substitution or step-wise using
incremental substitutions. Fig. 6 describes the generation of a
graph G for a template T given a complete valid substitution S.
Graphs are represented as pairs comprising a set of annotated ver-
tices and a set of annotated edges. Nii denotes the copy of the inter-
nal node Ni in the ith iteration of a graph Gi and  þ represents the
addition of nodes or edges together with any associated annota-
tions to an existing graph as required. The functions copye and
copyi generate a copy of the external nodes, edges and annota-
tions of a template and internal nodes, edges and annotations of
a zone respectively.
Generation may also occur in a step-wise fashion, e.g. when a
larger template is instantiated through several service calls by
the client software. The initial instantiation phase must be exe-
cuted but then the state of the generated graph may be saved.
Instantiations of individual zones may then be executed as needed
and the graph state updated at each step. After all zone iterations
have been completed a final phase would be executed in which
the initial and terminal states of any series zone present are gener-
ated and added to the graph. In this scenario, minimum and max-
imum bounds on zone iterations must be checked after the final
phase and the graph state discarded if the conditions are not
met. Further implementation details are discussed in Section 4.3.3.4. Examples of generated graphs
To illustrate the generation process, consider the valid instanti-
ation for template T1 that is shown in Fig. 7 alongside the corre-
sponding generated graph G1. As previously noted, the template
contains no zones and so all that occurs is the substitution of the
external variables and value variables with those identifiers and
values given by the instantiation.
Now consider the instantiation and provenance graph shown in
Fig. 8 generated from the template T2 with a parallel type zone
given in Fig. 4. Generation of the zone results in the creation of
forking nodes at act1 and ent-w and synchronising nodes at
ent-v and ent3. The internal node var:x has been instantiated
in the two iterations of the zone as ent-x1 and ent-x2 and the
other variables of the zone are processed similarly. Note that
because the node var:v was annotated as a graft node, the node
ent-v may represent a node from a pre-existing provenance
graph.
Fig. 9 illustrates the provenance graph generated from the tem-
plate T3 given in Fig. 5, using the same instantiation. The series
type zone results in the generation of two iterations joined by a
recursive edge between the nodes ent-u1 and ent-x2. The nodes
act and ent-w are joined to the first iteration and ent-v and
ent3 to the final iteration. Again ent-v may belong to a
Fig. 6. Generation algorithm.
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given in Fig. 8.4. Results
In order to demonstrate the applicability of the template-based
data provenance architecture to providing the relevant audit trail
for decision support systems, we have implemented such an archi-
tecture within the context of the TRANSFoRm project. The starting
point for defining the provenance use cases was expressing their
requirements as a set of basic provenance related questions,
describing the provenance information that we require to be auto-
matically recorded and available through our decision support
system:1. Which decision support user was responsible for initiating a
decision support tool session that resulted in a specific diag-
nostic recommendation being generated on a certain date?
This is a typical audit-style question that assigns responsibility
for the diagnosis made.
2. What authentication was used for a user responsible for a
certain action? This type of question investigates the correct-
ness of the authentication for a particular action.
3. What clinical evidence cues (presenting symptoms) sup-
ported the diagnosis of a particular diagnostic condition?
The input data provided to the diagnostic task needs to be
persisted in order to validate the recommendation made.
4. What clinical evidence data set(s) was a decision support
recommendation based on? In addition to the presenting
symptoms, it is also important to understand what evidence
base was used to generate the recommendation.
Fig. 7. Graph G1 generated from T1.
Fig. 8. Graph G2 generated from T2.
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Fig. 9. Graph G3 generated from T3.
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the evidence base? An example of taint analysis, this type of
question allows us to find all instances where a potentially
incorrect evidence base was used and to trace the affected
patients.
6. Which exact versions of the EHR system and the DSS were
used in a particular diagnosis? Details about the software
tools present in a diagnosis, allowing the user to investigate if
there are correlations between certain diagnosis and the soft-
ware used.
These questions could be asked by an internal or external audi-
tor, either directly, if the role is performed by a system administra-
tor, or via a dedicated user interface. In addition, questions 3. and
4. could be asked by a researcher or clinician wanting to learn more
about the guidelines currently in use, via an appropriate user inter-
face. Finally, the latter three questions are highly relevant for
investigating potential errors in the system and could be per-
formed by the DSS developer’s software team, most likely through
a set of direct queries.
One could think of further provenance questions that could be
asked about the operation of a decision support system, most nota-
bly around the provenance of the evidence base itself and the cre-
ation and management of rules therein, however in the
TRANSFoRm project, the evidence base was manually curated
and thus not suitable for inclusion in our use cases.
4.1. Representing DSS concepts as PROV annotations
One strength of using PROV as the provenance representation
language is that it allows for provenance nodes and edges to beannotated with key-value pairs. In order to precisely define the
items that are being captured in provenance traces, we have
assigned each node an ontological concept and a value, thus allow-
ing provenance graphs to be queried using precise semantics.
The ontological concepts are drawn from three ontologies:
TRANSFoRm Software Profile ontology (TRANSFoRm_Soft-
wareProfile) that comprises generic security and authentication
terms, TRANSFoRm Clinical Informatics ontology (TRANS-
FoRm_rcto) that contains clinical research concepts including
decision support, and TRANSFoRm Clinical Informatics Provenance
ontology (TRANSFoRm_rctpo) that maps TRANSFoRm_rcto
classes onto PROV terms [39]. These ontologies are implemented
in OWL and in addition to decision support, cover the full range
of Learning Health System concepts in observational studies and
clinical trials that were required by TRANSFoRm.
TRANSFoRm_SoftwareProfile’s design ensures that each
user action in the system can be traced back to the login session
during which it happened. This is done using OpenSession and
CloseSession classes and the SAMLAssertion, Session and
UserName data entity classes, reflecting the fact that TRANSFoRm
used Security Assertion Markup Language (SAML) to implement
its security framework. The OpenSession and CloseSession
describe the activities related when a user opens or closes an appli-
cation. The former activity uses the data provided by authentica-
tion services in form of SAML entities, identifying the person
accessing the application. This activity generates a Session object,
which is linked with the following activities during the system exe-
cution, including the CloseSession.
TRANSFoRm_rcto contains classes and relationships relevant to
decision support systems, covering clinical evidence and its use in
the diagnostic process. These include activities associated with
Table 1
TRANSFoRm ontological terms mapped onto provenance concepts in PROV-O.
TRANSFoRm concept Provenance concept
TRANSFoRm_SoftwareProfile#SAMLAssertion Entity
TRANSFoRm_SoftwareProfile#Session Entity
TRANSFoRm_SoftwareProfile#User Agent
TRANSFoRm_SoftwareProfile#UserName Entity
TRANSFoRm_SoftwareProfile#OpenSession Activity
TRANSFoRm_SoftwareProfile#CloseSession Activity
rctpo#CE_Repository Agent
rctpo#Patient Agent
rctpo#DSS_system Agent
rctpo#EHR_system Agent
rctpo#CollectDiagnosticCues Activity
rctpo#PatientDiagnosisCueSet Entity
rctpo#EvidenceComparison Activity
rctpo#CE_MatchingRulesSet Entity
rctpo#DSS_Recommendation Entity
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(CE_Repository), and its use by the decision support system
(DSS_system). While collecting clinical evidence rules, Col-
lectDiagnosticCues activities update the CE_Repository.
During the diagnostic task, a set of diagnostic cues,
CE_PatientDiagnosisCueSet, are compiled and used to per-
form EvidenceComparison resulting in a set of matching rules,
CE_MatchingRulesSet and the final diagnosis recommendation
DSSRecommendation. TRANSFoRm_rctpo creates subclasses of
relevant TRANSFoRm_rcto classes that are also subclasses of
PROV-O ontology [40] concepts, creating identifiers and text labels
which are then used as PROV annotations onto provenance tem-
plate nodes, as shown in Table 1.
4.2. Clinical decision support templates
Two use cases for the TRANSFoRm decision support system
were defined and expressed in the form of provenance templates.
The first describes the user logging into the system and getting
authenticated by the security framework, while the second sup-
ports provenance collection during evidence consumption and
subsequent clinical recommendation provided by the deployed
evidence repository accessed by the decision support tool itself.
Note that the two template instantiations are invoked by two dif-
ferent pieces of software in the TRANSFoRm system, the former by
the security subsystem and the latter by the decision support tool
itself.
In order to represent the semantic categories, each node in the
template is further constrained by the ontological annotationsFig. 10. Session template showing the login activity produdescribed in Section 4.1 and shown as PROV key-value attribute
pairs in the grey boxes.
The template in Fig. 10 shows the task of a user logging into the
decision support system via TRANSFoRm secure middleware, using
Security Assertion Markup Language (SAML) authentication and
obtaining a session object which is later used to authorise the user
to perform actions on the system.
The template in Fig. 11 depicts the operation of the diagnostic
decision support system. External nodes var:ehr and var:pa-
tient denote the Electronic Health Record system used and the
patient presenting for diagnosis, respectively, while var:ceRepo
and var:dss represent the clinical evidence repository used and
the decision support system. The zone represents a single diagnosis
task for the patient, of which it is assumed there will be several,
with different sets of cues (var:cueSet) producing different diag-
nostic recommendations (var:diagRec). Patient symptoms are
noted (var:collectCues) and used to generate a record of the
patient visit var:patientVisit, which is used by the decision
support system var:dssSys to make a comparison (var:evi-
denceComp) against the available clinical evidence in its knowl-
edge base var:ceRepo to generate a matching set of rules
var:matchSet and a diagnostic recommendation var:diagRec.
Note that the two templates overlap on the session entity,
which is a graft node in the second template, so there needs to
be one login provenance fragment for each diagnosis fragment.
One example of the provenance data collected in the TRANSFoRm
DSS system is shown in Fig. 12, visualised in the Neo4J database.
4.3. Provenance template server architecture
The architecture of the system is illustrated in Fig. 13. The over-
all structure is simple. The provenance server itself is accessible as
a web service via an endpoint offering a RESTful API with the data
stored using a MySQL relational database with a D2RQ relational-
to-RDF adapter [41] allowing querying via SPARQL language that
is targetted at semantically annotated data. The data is also trans-
ferred into a Neo4j graph database using Extract-Transform-Load
(ETL), with an instance of the Neo4j web server allowing captured
data to be queried and visualised by users via a browser-based
interface using the Cypher query language [42].
The main subcomponent of the server is the template engine,
which is responsible for validating substitutions for a given tem-
plate and generating the subsequent graph. Provenance graphs
are converted to and from the database format by a translator com-
ponent. Since Neo4j employs a higher-level, graph-theoretic model
by a translator component, the ETL represents PROV node types as
Neo4j node labels and PROV annotations as Neo4j properties.cing a session entity and a security certificate entity.
Fig. 11. Diagnosis template where a set of diagnosis is made for a patient, each producing diagnostic recommendations.
Fig. 12. Instantiated template in Neo4J database.
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Fig. 13. Server architecture. Graphs stored in the main database are transferred to Neo4J graph database via Extract-Transform-Load (ETL) to facilitate interactive querying.
14 V. Curcin et al. / Journal of Biomedical Informatics 65 (2017) 1–21As described in Section 3.2, the current prototype implementa-
tion employs a graph model similar to that of Neo4j. Graphs are
described in terms of vertices and edges which may be annotated
by dictionaries of named data values. Templating, provenance and
user-defined data are kept in separate namespaces. This design
allows the engine to be agnostic as regards the provenance stan-
dard used by the server, whether that be PROV, the Open Prove-
nance Model (OPM) or any other. However, the remaining
components, the REST endpoint, provenance validator and graph
translator are specific to a particular standard and must be imple-
mented on a case-by-case basis along with adapters for the tem-
plate engine.
The main use case is that for storing a graph generated from a
template and accompanying instantiation and proceeds as follows.
Given a description of the provenance template and instantiation
for that template, both are serialised in JSON format and sent to
the REST endpoint in a single API call to generate and store the
data. After being received by the server, this description is deseri-
alised and then passed to the template engine where it is first val-
idated in order to ensure that the substitution is valid for the
template provided. If this succeeds then the graph synthesis com-
ponent proceeds to generate the expanded graph following the
algorithm described in Fig. 6. This graph is then run through
the provenance validator component which checks the validity of
the generated graph. If the graph is valid then it is passed to the
translator which commits this to the database. Note that if a tem-
plate includes graft nodes then the provenance validator may need
to query the database about existing graphs in order to assess the
validity of the generated graph. The second use case, the storage of
a complete graph is a subcase of the first. A description of the graph
is presented to the server directly via the endpoint at which point
it is immediately handed to the provenance validator component
rather than to the template engine, and then stored if deemed
valid.
As discussed in Section 3.3, it may be also be desirable to
generate graphs from a template in a step-wise rather than
single-step fashion. In this situation, three API methods would bepublished. An initialisationmethod would first provide a template
and a substitution for external variables and value variables of the
template. Following this, one or more calls to a zone iteration
method would then be made for each zone within the template
providing substitution data for the instantiation of a new iteration
of the zone. A finalization method would then signal that a tem-
plate was considered complete which would trigger the comple-
tion of series type zones, validation of the instantiation and of
the generated graph. Intermediate graph states would be com-
mited as temporary graph fragments in the database and either
commited fully or rolled back following final validation.
4.4. Provenance data collected
The TRANSFoRm diagnostic decision support system was evalu-
ated using a high-fidelity simulation of the clinical consultation
using real EHR system in a simulated clinic environment. The eval-
uation employed 34 real physicians and a series of actors reenact-
ing real patient scenarios, around three presenting problems (chest
pain, shortness of breath and dyspnea) resulting in a total of 408
patient encounters. Each clinician would be logging into a system
once per day, and producing one diagnostic template instantiation
with 3–4 zone repetitions per encounter. In a real-world clinic with
8 general practitioners, seeing 40 patients per day, which is stan-
dard for an inner London practice, this would translate into around
1000 zone instantiations per day, giving us a scale of the data size
and velocity involved in a real life environment.
4.5. Queries developed
The traditional way of querying provenance data uses SPARQL
as a semantically enabled query language. In our architecture,
the provenance data store accepts SPARQL queries and returns
answers. However, we are also interested in the interactive query
capabilities, for which the Neo4J database front-end has suitable
tooling via its Cypher query language [42] and browsing features.
In this type of queries, the reply serves as a starting point for
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Thus, in order to demonstrate the viability of using provenance
graphs as the audit trail of the decision support tools, we have
mapped our initial set of questions onto queries in both SPARQL
and the Cypher graph query language, making use of the ontologies
we developed. Note that for readability in Cypher queries we are
using human readable labels derived from ontological categories.
Query 1:Which decision support user was responsible for initi-
ating a decision support tool session that resulted in a specific
diagnostic recommendation being generated on a certain date?
SPARQL:
select ?userName
?oss provo:wasControlledBy ?userName
?oss rdf:type TRANSFoRm_SoftwareProfile:
OpenSession
?s provo:wasGeneratedBy ?oss
?s rdf:type TRANSFoRm_SoftwareProfile:Session
?cdc provo:used ?s
?cdc rdf:type rctpo:collectDiagnosticCues
?dcs rdf:type rctpo:diagnosticCueSet
?dcs provo:wasGeneratedBy ?cdc
?ec rdf:type rctpo:EvidenceComparison
?ec provo:used ?dcs
dssRecommendation.getProvURI() provo:
wasGeneratedBy ?ec
Cypher:
MATCH (n:ENTITY {Concept:‘‘DSS Recommendation",
Value:‘‘Appendicitis, unqualified",
Timestamp:‘‘2015-02-24T00:00:00"})-[⁄]->(m:ENTITY
{Concept:‘‘UserNameAgent"})
RETURN m.Value;
Query 2: What authentication was used for a user responsible
for a certain action?
SPARQL:
select ?saml
?oss provo:used ?saml
?oss rdf:type TRANSFoRm_SoftwareProfile:
OpenSession
?s provo:wasGeneratedBy ?oss
?s rdf:type TRANSFoRm_SoftwareProfile:Session
action.getProvURI() provo:Used ?s
Cypher:
MATCH (m:ACTIVITY {Concept:‘‘Collect Diagnostic
Cues")-->
(n:ENTITY {Concept:‘‘Session"}) --()->(o:ENTITY {C
oncept:‘‘SAMLAssertion"})
WHERE ID(m)=346204
RETURN o.Value;
Query 3:What clinical evidence cues supported the diagnosis of
a particular diagnostic condition?
SPARQL:select ?clEvidenceRepository
datasetRecommendation.getProvURI() provo:
wasDerivedFrom ?p
?p rdf:type provo:Activity
?p used ? clEvidenceRepository
?clEvidenceRepository rdf:type rctpo:
CE_Repository
Cypher:
MATCH (n:ENTITY {Concept:‘‘DSS Recommendation",
Value:‘‘Acute pyelonephritis"})-->()-->
(m:ENTITY {Concept:‘‘Diagnostic Cue Set"})
RETURN distinct m.Value;
Query 4: What clinical evidence data set(s) was a decision sup-
port recommendation based on?
SPARQL:
select ?clEvidenceRepository
datasetRecommendation.getProvURI() provo:
WasGeneratedFrom ?p
?p rdf:type provo:Activity
?p provo:wasControlledBy ?clEvidenceRepository
?clEvidenceRepository rdf:type rctpo:
CE_Repository
Cypher:
MATCH (n:ENTITY {Concept:‘‘DSS Recommendation"})
-[:WAS_CONTROLLED_BY]->
(m:ENTITY {Concept:‘‘Clinical Evidence
Repository"})
WHERE ID(n)=346530
RETURN m.Value;
Query 5: What patients were diagnosed using a particular ver-
sion of the evidence base?
SPARQL:
select ?p
?p rdf:type rctpo:Patient
?cdc rdf:type rctpo:collectDiagnosticCues
?cdc provo:wasControlledBy ?p
?dcs rdf:type rctpo:diagnosticCueSet
?dcs provo:wasGeneratedBy ?cdc
?ec rdf:type rctpo:EvidenceComparison
?ec provo:used ?dcs
?ec provo:wasControlledBy ?cer
?cer rdf:type rctpo:clinicalEvidenceRepository
?cer rctpo:hasVersion ‘‘2.3"
Cypher:
MATCH (p:AGENT {Concept:‘‘Patient"}) <-[⁄]-
(n:ENTITY {Concept:‘‘Evidence Comparison"})-[:
WAS_CONTROLLED_BY]-->
(continued on next page)
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WHERE m.Version=2.3
RETURN distinct p.Value;
Query 6: Which exact versions of the EHR system and the DSS
were used in a particular diagnosis?
SPARQL:
select ?ehr_version, ?dss_version
?ehr rctpo:hasVersion ?ehr_version
?dss rctpo:hasVersion ?dss_version
?ehr rdf:type rctpo:EHR_system
?dss rdf:type rctpo:DSS_system
?cdc rdf:type rctpo:collectDiagnosticCues
?cdc provo:wasControlledBy ?ehr
?cdc provo:wasControlledBy ?dss
?dcs rdf:type rctpo:diagnosticCueSet
?dcs provo:wasGeneratedBy ?cdc
?ec rdf:type rctpo:EvidenceComparison
?ec provo:used ?dcs
dssRecommendation.getProvURI() provo:
wasGeneratedBy ?ec
Cypher:
MATCH (n:ENTITY {Concept:‘‘DSS Recommendation"})-
[⁄]->
(m:AGENT {Concept:‘‘DSS system"}),
n-[⁄]->(o:AGENT {Concept:‘‘EHR system"})
WHERE ID(n)=346530
RETURN m.Value, o.Value;
As can be seen from the structure of implemented queries, the
SPARQL queries operating on the RDF representation are, in effect,
recreating the structure of the instantiated template to ask ques-
tions. Cypher queries meanwhile can make use of generic graph
connectivity queries through the -[⁄]-> construct, which, while
computationally expensive, provides for a more expressive query
construction. Furthermore, further navigation and querying from
the original result is simpler and faster in Neo4J, which supports
the exploratory investigation of provenance traces. Broadly speak-
ing, the strength of Cypher is in processing queries once the entry
point has been found [43], while SPARQL running on RDF represen-
tations is better at aggregated queries that need to traverse the
entirety of the database. However, with improved indexing capa-
bilities in Neo4J v3, this may be subject to change and we are plan-
ning to do the full comparison on a larger, simulated, data set as
part of future work.
5. Discussion
In Section 3, nine requirements were defined for achieving
reproducibility in decision support systems, which we now revisit
to demonstrate how our solution addresses them:
1. System transparency. The provenance trace in any of its forms
provides the insight into the workings of the decision support
system, with the granularity defined by the ontologies used,
allowing varying levels of detail.
2. Auditability of recommendations. To ensure recommenda-
tions made are auditable, the system must guarantee that therequired subset of information is present in the provenance
traces. Templates provide exactly this functionality, by specify-
ing the metadata that will be captured and supporting queries
such as Query 3 and Query 5 in Section 4.5.
3. Understandability of data. Use of domain ontologies (e.g.
TRANSFoRm’s Clinical evidence ontology) in the provenance
node annotations allows queries to be posed in terms of stan-
dardised terminologies.
4. Validation readiness. Provenance templates are independent
of any concrete implementation and the architecture presented
is model-driven. Thus, the model can be validated separately
from the software tool.
5. Traceability of evidence. In the provenance model we have
developed, each version of an evidence base is considered a sep-
arate state, and thus is modelled as a separate entity, with each
recommendation connected to a single evidence base version.
This enables answering questions such as the one posed in
Query 4 and Query 6 in Section 4.5.
6. Reproducibility of recommendations. Rule engines used in
decision support systems have to be deterministic if they are
to pass validation. Provenance data provides the historical data
to conduct that validation and search for the presence of
instances where the same input may have resulted in different
outputs.
7. Responsibility. By storing provenance traces in connected
graphs containing the details of the security and authentication
mechanisms used, the use of authentication templates guaran-
tees that each action can be traced back to the user or software
responsible, as shown in Query 1, Query 2, and Query 6 in
Section 4.5.
8. Privacy and security. The provenance data stored contains the
unbroken chain of actions that transformed various pieces of
data in the system. If this includes confidential information that
should not be presented to the system users, there are several
techniques for abstracting parts of provenance data according
to predefined security policies [44–46].
9. Usability and scalability. The provenance system is hidden
away from the decision support system users, so by implement-
ing light-weight components and asynchronous REST calls, we
ensure that its presence does not impede the clinical consulta-
tion process by introducing delays. With regards to the scalabil-
ity, the use of templates allows us to precisely determine what
will be the volume of the provenance data collected and the
velocity at which it accumulates, allowing the system adminis-
trators to implement appropriate storage policies.
By addressing these, we believe that our approach can be used
as a basis for a wide variety of decision support applications. It
should be noted that the template design process should always
be done in collaboration with the domain experts to ensure cor-
rectness and applicability, and that we do not expect the two
TRANSFoRm templates to be necessarily sufficient for each possible
use case, merely to serve as starting points, together with the
ontologies developed. Given that the surrounding architecture is
domain-agnostic, we can reasonably expect that it can support
use cases at varying levels of complexity, e.g. a production quality
implementation would require a conformance testing suite and
independent validation of templates developed, ensuring, among
other things, that domain ontology constraints are not violated.
The SPARQL and Cypher interfaces allow system developers to
quickly query the accrued provenance data, but in order to expose
this information to a broader range of end-users, such as institu-
tional and external auditors, commissioning groups, and even clin-
icians, more visual tooling is necessary. TRANSFoRm implemented
two prototype front-end tools: a web interface containing several
representative queries such as the ones above, hiding away the
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eters and obtain back the results in graph form; and a set of inter-
active reports containing tabular and chart information,
implemented in Eclipse Business Intelligence Reporting Toolkit
(BIRT). This approach is currently being explored further by the
authors in a follow-up industrial collaboration that shall develop
end-user query tools.
Historically, a major challenge for adoption of decision support
systems has been the lack of transparency in the recommendations
and rules that those recommendations have been based on. In order
to evaluate whether provenance technologies can make a tangible
difference in clinical practice, and determine whether this informa-
tion can benefit clinicians directly, provenance elements need to be
embedded into a DSS user interface and a full usability study, e.g.
using Technical Acceptance Model, shall be necessary. Thus, evalu-
ation of provenance technologies should encompass both the com-
putational and other operational cost involved in running the tools,
and the effort needed to design the necessary models and queries
should also be measured. Another issue of note is the quality of col-
lected provenance data, its completeness and accuracy, which
should be improved by the use of provenance templates. In order
to evaluate this, a separate method of data collection should be
specified for each provenance question, and the two compared
against each other. These and other software engineering chal-
lenges related to provenance are being addressed through the work
on PRIME methodology [47]. The authors are applying and extend-
ing this work within the LHS-Stroke secondary stroke prevention
project that is part of the CLAHRC South London programme.3
While this paper focused on diagnostic decision support sys-
tems, because this was the DSS use case in the TRANSFoRm project,
identical issues arise in other types of DSS such as patient manage-
ment tools and higher level reporting tools such as management
portals used by commissioners, insurers, and health administra-
tors. Indeed some of these have been found to have more impact
on patient care than diagnostic systems [21].5.1. Recent developments
The practical need for research into the area of computable
provenance for diagnostic decision support has been starkly high-
lighted by recently reported events in UK general practice sur-
rounding incorrect recommendations being made by a decision
support system [48]. The QRISK 2 score is a validated, accepted
and widely used decision support aid for predicting the cardiovas-
cular risk in patients in the UK, that is integrated with EHR systems
via a parameterised programmatic interface allowing triggering of
rules from within the EHR. One particular implementation of the
QRISK2 score with a widely used general practice EHR system,
was found to be overstating the reported cardiovascular risk in
some patients resulting in the wrong guidance to the physician
to advise patients to take statin medication to lower that risk. This
has resulted in a full investigation by the Medical and Health Prod-
ucts Regulatory Agency (MHRA) in the UK. The initial suspicion has
focussed on the communication of patient data between the EHR
and the QRISK2 calculator, rather than the implementation of the
QRISK2 tool itself. This has resulted in the need for the EHR vendor
in question to identify GP practices to notify potentially impacted
patients and to re-examine their cardiovascular risk. The prove-
nance work as described in this research can be seen to be highly
applicable in such a logistically difficult scenario. This damage lim-
itation is a classic example of provenance taint analysis as
described in Section 4, and in such scenario our system could be
used to identify:3 http://www.clahrc-southlondon.nihr.ac.uk/stroke. Potential GP practices where the QRISK2 score has been used to
give diagnostic recommendations. (similar to Query 1, looking
into practice instead of a user)
 Diagnostic recommendations actually made for identifiable
patients from identifiable EHR systems that actually used the
QRISK2 tool. (similar to Query 5)
 Theactualpatient cue sets thatwere submitted to theQRISK2 tool
interface to make the diagnostic recommendations. (Query 3)
 The returned diagnostic recommendation risk score result for
each individual patient involved. (similar to Query 5, including
risk score in the template model)
Due to this unfortunate incident, we expect the topics of trust
and auditability of decision support systems to come even more
to the forefront.
5.2. Tracing evidence evolution
In more generic decision support systems that rely on a collec-
tion of rules that are combined to produce recommendations, the
questions on the lineage of rules used to produce a recommenda-
tion become important: What data sets and algorithms were used
in rule production? How was the rule validation performed? We
considered these questions during the TRANSFoRm project, and
produced example templates that would satisfy these questions,
but they were not implemented at this stage due to the data min-
ing framework remaining separate from the rest of the system. In
this extension to the model, each addition, change, or deletion of
a rule in the evidence base is tracked, whether the rule has been
manually modified or a result of an automated data mining
algorithm.
5.3. Related work
The prototype of template-based provenance was introduced in
its early form in [49,50] and successfully demonstrated the feasi-
bility of using provenance templates to support a large, heteroge-
neous software infrastructure, albeit missing the theoretical
foundation and full architecture presented here. A separate effort
at Southampton [51] is currently looking into lower-level prove-
nance templates that abstract individual PROV variables, rather
than larger graph fragments. The instantiation then proceeds by
performing cross-products of all variable value spaces, as restricted
by constraints. The concept of substructures in provenance graphs
has also been researched in the context of SPARQL queries for RDF
provenance repositories and generic graph fragment queries that
use a graph motif with a set of constraints on that motif [52].
Related efforts have also been made in the area of graph summari-
sation [53] which use the graph structure as a basis for summaris-
ing and compressing relational knowledge by detecting patterns
and compressing structural knowledge encoded within relational
graphs, including repetitive or sequential structures. Finally, a
body of work exists in abstracting provenance graphs for security
purposes. ZOOM system uses the concept of user views to abstract
nodes that are not of interest to the consumer [54]. The TACLP [44],
ProvAbs [45], and ProPub [46] approaches use security policy def-
initions to determine which components of the provenance graph
to include and which to abstract.6. Conclusions and future work
A defining characteristic of the Learning Health System is the
trust that must be placed in every aspect of the system [5]. The par-
ticipants in the LHS must be able to gain insight into its workings if
they are to put faith in its actions and entrust it with their data.
18 V. Curcin et al. / Journal of Biomedical Informatics 65 (2017) 1–21Furthermore, the system must possess introspective qualities in
order to be able to learn about itself and continuously improve,
engendering a Virtuous Cycle of Health Improvement. This implies
capabilities for data and knowledge sharing between the research
and clinical actors, under clear and automatically enforced privacy
and security rules. A semantically clear and unambiguous prove-
nance trace provides a mechanism for such sharing.
This paper has looked into the reproducibility challenges facing
decision support systems, guided by the LHS paradigm, and pro-
posed a solution based on data provenance technologies and
abstract provenance template constructs. The semantic complexity
of the medical domain modelled was modelled using ontologies
annotated onto provenance graphs, and the software architecture
used the templates to facilitate provenance capture from the deci-
sion support tool. The work was originally prototyped in the diag-
nostic decision support system developed within the TRANSFoRm
project where it was used to capture data from over four hundred
simulated diagnostic patient encounters and key analytical queries
on that data were shown.
Ultimately, this work contributes to the efforts in integrating
trust into computerised decision support systems, enabling trans-
parency and auditability by creating a basis for implementing val-
idation mechanisms. The complexity of decision support systems
offers numerous opportunities for problems to arise, from quality
of data capture and accuracy of EHR interactions via usability
issues to algorithmic errors in rule design. Thus, their increased
use puts more and more focus on the techniques for ensuring cor-
rectness of the tasks involved. Data provenance offers the mecha-
nism to achieve this, and through use of provenance templates,
we have shown how such infrastructure can be implemented in
the context of decision support systems.
In the era of Big Data, deep learning systems such as IBMWatson,
and other technologies that often rely on black-box analytical envi-
ronments, it is of paramount importance to support transparency in
computerised systemswhich actionsmay have direct consequences
on human lives. A particularly dangerous assumption of some Big
Data evangelists is that with a sufficiently large data, correlation
can replace causality in our analytical models. While this may be
perfectly fine for market analysis questions such as investigating
customer churn or supermarket shopping baskets, medical research
in particular depends on full understanding of finer points such as
bias, data quality, and statistical significance to derive its conclu-
sions. Thankfully, there is an increasing understanding of the fact
that we require not just intelligentmachines but intelligible machi-
nes [55]. Rather than avoiding Big Data technologies, we need to
understand which aspects of it are well-suited to medical research,
and then build research software frameworks that support trans-
parency, auditability, replicability and reproducibility [56].
The version of the DSS provenance infrastructure employed in
TRANSFoRm is currently being updated for use by further projects,
such as the DSS for prevention of secondary stroke in patients in
South London. The tool, developed as part of the CLAHRC South
London programme,4 has been designed by the team at King’s Col-
lege London with key stakeholders including clinicians, patients,
and commissioners, and the provenance module will provide audi-
bility and traceability of decisions made with the tool. With the
recent changes in scalability support in Neo4J, we intend to do away
with the relational/RDF store and use Neo4J as our main database
storage, providing a SPARQL query front end for backwards compat-
ibility. Furthermore, we plan to add more templates that cover non-
diagnostic decision support scenarios and implement some more
advanced PROV concepts such as hyperedges representing relations
between more than two nodes.4 http://www.clahrc-southlondon.nihr.ac.uk/.Conflicts of interest
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Appendix A. Full PROV-N specification of graphs shown in
figures
A.1. Fig. 3
entity(var:x, [attr=vvar:a])
activity(var:y)
entity(ent1)
agent(var:z)
activity(act1)
wasGeneratedBy(var:x, var:y)
used(var:y, ent1)
wasAssociatedWith(var:y, var:z)
wasGeneratedBy(ent1, act1)A.2. Fig. 4
entity(var:x, [attr=vvar:a, zone:id=zone1,
zone:type=parallel, zone:min=2])
activity(var:y, [zone:id=zone1,
zone:type=parallel, zone:min=2])
entity(var:t, [zone:id=zone1, zone:type=parallel,
zone:min=2])
agent(var:z, [zone:id=zone1, zone:type=parallel,
zone:min=2])
activity(var:u, [zone:id=zone1,
zone:type=parallel, zone:min=2])
wasGeneratedBy(var:x, var:y)
used(var:y, ent1)
wasAssociatedWith(var:y, var:z)
wasGeneratedBy(ent1, act1)
entity(ent2)
activity(act2)
entity(var:w)
entity(var:v)
entity(ent3)
entity(var:v, [pgt:graft])
wasGeneratedBy(ent2, act2)
used(act2, var:x)
wasDerivedFrom(var:w, var:x)
used(var:u, var:v)
used(var:u, ent3)
edical Informatics 65 (2017) 1–21 19A.3. Fig. 5V. Curcin et al. / Journal of Biomentity(var:x, [attr=vvar:a, zone:id=zone1,
zone:type=serial, zone:max=8])
activity(var:y, [zone:id=zone1, zone:type=serial,
zone:max=8])
entity(var:t, [zone:id=zone1, zone:type=serial,
zone:max=8])
agent(var:z, [zone:id=zone1, zone:type=serial,
zone:max=8])
activity(var:u, [zone:id=zone1, zone:type=serial,
zone:max=8, pgt:recEntry=var:x, pgt:recType:
used])
wasGeneratedBy(var:x, var:y)
used(var:y, ent1)
wasAssociatedWith(var:y, var:z)
wasGeneratedBy(ent1, act1)
entity(ent2)
activity(act2)
entity(var:w)
entity(var:v)
entity(ent3)
entity(var:v, [pgt:graft])
wasGeneratedBy(ent2, act2)
used(act2, var:x)
wasDerivedFrom(var:w, var:x)
used(var:u, var:v)
used(var:u, ent3)A.4. Fig. 7
entity(ent-x, [attr=val-a])
activity(act-y)
entity(ent1)
agent(agt-z)
activity(act1)
wasGeneratedBy(ent-x, act-y)
used(act-y, ent1)
wasAssociatedWith(act-y, agt-z)
wasGeneratedBy(ent1, act1)A.5. Fig. 8
entity(ent-x1, [attr=val-a1])
activity(act-y1)
entity(ent-t1)
agent(agt-z1)
activity(act-u1)
wasGeneratedBy(ent-x1, act-y1)
used(act-y1, ent-t1)
wasAssociatedWith(act-y1, agt-z1)
wasGeneratedBy(ent-t1, act-u1)
entity(ent-x2, [attr=val-a2])
activity(act-y2)
entity(ent-t2)
agent(agt-z2)
activity(act-u2)wasGeneratedBy(ent-x2, act-y2)
used(act-y2, ent-t2)
wasAssociatedWith(act-y2, agt-z2)
wasGeneratedBy(ent-t2, act-u2)
entity(ent2)
activity(act2)
entity(ent-w)
entity(ent-v)
entity(ent3)
wasGeneratedBy(ent2, act2)
used(act2, ent-x1)
used(act2, ent-x2)
wasDerivedFrom(ent-w, ent-x1)
wasDerivedFrom(ent-w, ent-x2)
used(act-u1, ent-v)
used(act-u2, ent-v)
used(act-u1, ent3)
used(act-u2, ent3)A.6. Fig. 9
entity(ent-x1, [attr=val-a1])
activity(act-y1)
entity(ent-t1)
agent(agt-z1)
activity(act-u1)
wasGeneratedBy(ent-x1, act-y1)
used(act-y1, ent-t1)
wasAssociatedWith(act-y1, agt-z1)
wasGeneratedBy(ent-t1, act-u1)
entity(ent-x2, [attr=val-a2])
activity(act-y2)
entity(ent-t2)
agent(agt-z2)
activity(act-u2)
wasGeneratedBy(ent-x2, act-y2)
used(act-y2, ent-t2)
wasAssociatedWith(act-y2, agt-z2)
wasGeneratedBy(ent-t2, act-u2)
entity(ent2)
activity(act2)
entity(ent-w)
entity(ent-v)
entity(ent3)
wasGeneratedBy(ent2, act2)
used(act2, ent-x1)
wasDerivedFrom(ent-w, ent-x1)
used(act-u2, ent-v)
used(act-u2, ent3)
used(act-u1, ent-x2)A.7. Fig. 10
entity(var:session, [type:
PROV_SoftwareProfile#Session])
entity(var:securityCertificate, [type:
PROV_SoftwareProfile#SAMLAssertion])
activity(var:open, [type:
(continued on next page)
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agent(var:ehrSystem, [pgt:graft, type:
rctpo#EHR_system])
agent(var:user, [type:
PROV_SoftwareProfile#User])A.8. Fig. 10
entity(var:matchSet, [zone:id=diagnosis,
zone:type=parallel, type:
rctpo#CE_MatchingRulesSet])
entity(var:diagRec, [zone:id=diagnosis,
zone:type=parallel, type:
rctpo#DSS_Recommendation])
activity(var:evidenceComp, [zone:id=diagnosis,
zone:type=parallel, type:rctpo#EvidenceCompari
son])
entity(var:cueSet, [zone:id=diagnosis,
zone:type=parallel, type:rctpo#PatientDiagno
sisCueSet])
agent(var:ceRepo, [pgt:graft, type:
rctpo#CE_Repository])
activity(var:collectCues, [zone:id=diagnosis,
zone:type=parallel, type:rctpo#CollectDiagnos
ticCues])
entity(var:session, [pgt:graft, type:
PROV_SoftwareProfile#Session])
agent(var:patient, [pgt:graft, type:
rctpo#Patient])
agent(ehr, [pgt:graft, type:rctpo#EHR_system])
agent(var:dss, [pgt:graft, type:rctpo#DSS_system])References
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